Scientific Rationale for the Use of Alpha-Adrenergic Agonists and Glucocorticoids in the Therapy of Pediatric Stridor

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr class="thead"><td align="left">Treatment modality</td><td align="left">Clinical outcomes</td></tr><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left"><i>α</i>AR-agonists:<br/><br/>(i) Nebulized racemic  epinephrine<br/>(ii) Nebulized (L) isomeric epinephrine</td><td align="left">(i) Transient improvements in croup symptom scores compared to placebo at 10 and 30 minutes after administration (duration 120 minutes) </td></tr><tr><td align="center" colspan="2"><hr/></td></tr><tr><td align="left">Glucocorticoids</td><td align="left">(i) Reduced rates of  postextubation stridor in adults and certain pediatric groups (i.e., high-risk patients)</td></tr><tr><td align="left">(i) Dexamethasone (0.15–0.6 mg/kg)</td><td align="left">(ii) Probable decrease in reintubation rates in select cases, but not in general adult and pediatric populations</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Clinical effects of <i>α</i>AR-agonists and glucocorticoids in postextubation stridor.

International Journal of Otolaryngology

tab4

Table 4

Table 4: Scientific Rationale for the Use of Alpha-Adrenergic Agonists and Glucocorticoids in the Therapy of Pediatric Stridor 